← Back to Search

Immunomodulatory Agent

Revlimid (Lenalidomide) for Myelodysplastic Syndrome

Phase 2
Waitlist Available
Led By Mark Heaney, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 weeks from baseline
Awards & highlights

Study Summary

This trial will test if a gene's expression can predict if a patient with myelodysplastic syndrome will respond to the study drug Revlimid.

Eligible Conditions
  • Myelodysplastic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 weeks from baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 weeks from baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Response Signature in Transfusion Dependent MDS Patients

Trial Design

1Treatment groups
Experimental Treatment
Group I: RevlimidExperimental Treatment1 Intervention
Revlimid (Lenalidomide) capsule taken orally once a day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Revlimid (Lenalidomide)
2009
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,433 Previous Clinical Trials
2,460,958 Total Patients Enrolled
Celgene CorporationIndustry Sponsor
444 Previous Clinical Trials
58,179 Total Patients Enrolled
Mark Heaney, MDPrincipal InvestigatorColumbia University
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Revlimid in Transfusion Dependent Patients
2010. "Revlimid in Transfusion Dependent Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01178814.
All > Lenalidomide > Revlimid
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top